title: Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenib.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Franck
authors.forename: Stéphane
authors.initials: S
authors.lastname: Barete
authors.forename: Philippe
authors.initials: P
authors.lastname: Moguelet
authors.forename: Benoît
authors.initials: B
authors.lastname: Blanchet
authors.forename: Agnès
authors.initials: A
authors.lastname: Carlotti
authors.forename: Stanislas
authors.initials: S
authors.lastname: Ropert
authors.forename: Marie Françoise
authors.initials: MF
authors.lastname: Avril
authors.forename: Camille
authors.initials: C
authors.lastname: Francès
authors.forename: Bertrand
authors.initials: B
authors.lastname: Billemont
authors.forename: François
authors.initials: F
authors.lastname: Goldwasser
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D005499:Folliculitis / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D007642:Keratosis / Q000139:chemically induced* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011494:Protein Kinases / Q000187:drug effects; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects*; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D000077157:Sorafenib
chemical_list: D020533:Angiogenesis Inhibitors; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D011494:Protein Kinases